drugset / Trial / NCT04634370
Fase I Clinical Trial on NK Cells for COVID-19
NaSingle-groupOpen-labelTreatment
Summary
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. This study aims to investigate the safety and efficacy of intravenous infusion of natural killer cells patients with COVID-19.
Timeline
- Start
- 2021-01-02
- Primary completion
- 2021-03-30
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | TROCULEUCEL | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | TROCULEUCEL | Cell therapy | 1e+07 cells/kg | Intravenous |